Company: ELV
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0001156039-25-000010
Chunk: 96

Company: Elevance Health, Inc.
Filing Date: 2025-02-20
Form: 10-K
Item: Item 5
Chunk 96
---
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

Market Information 

Our common stock, par value $0.01 per share, is listed on the NYSE under the symbol “ELV.” 

Holders

As of February 1, 2025, there were 46,307 shareholders of record of our common stock. 

Securities Authorized for Issuance under Equity Compensation Plans

The information required by this Item concerning securities authorized for issuance under our equity compensation plans is set forth in Part III, Item 12, “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” in this Annual Report on Form 10-K.

Issuer Purchases of Equity Securities

The following table presents information related to our repurchases of common stock for the periods indicated (in millions, except share and per share data):

PeriodTotal Numberof SharesPurchased1 AveragePrice Paidper ShareTotal Numberof SharesPurchased asPart ofPubliclyAnnouncedPrograms2 ApproximateDollar Valueof Shares thatMay Yet BePurchasedUnder theProgramsOctober 1, 2024 to October 31, 2024801,484 421.93 798,055 $10,774 November 1, 2024 to November 30, 20241,859,856 409.95 1,856,962 10,013 December 1, 2024 to December 31, 20241,858,281 383.93 1,857,988 9,300 4,519,621 4,513,005 

1Total number of shares purchased includes 6,616 shares delivered to or withheld by us in connection with employee payroll tax withholding upon exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders’ equity are shown net of these shares purchased.

2Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board evaluates periodically. During the year ended December 31, 2024, we repurchased 6,661,737 shares at an aggregate cost of $2,900 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock